← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Arisaph Pharmaceuticals, Inc.
Boston, MA
$2,618,563
Total funding
5
Grants
Funding over time
peak $1M · FY2011–15$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$2,618,563 · 5
By mechanism
R42$1,066,916 · 1
R41$1,052,862 · 3
R43$498,785 · 1
Investigators at Arisaph Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors$534,844
R42 · FY2014 · CA
A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors$532,072
R42 · FY2015 · CA
A Safe and Tolerable Niacin Analog for Treatment of Nonalcoholic Steatohepatitis$498,785
R43 · FY2015 · DK
A Small Molecule to Activate Cetuximab to Kill K-RAS Mutant Colorectal Tumors$266,641
R41 · FY2012 · CA
A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors$245,638
R41 · FY2011 · CA
A Small Molecule to Activate Tumor Immunity after PLX403 in V600E BRAF Melanoma$232,852
R41 · FY2013 · CA
A Small Molecule to Activate Tumor Immunity after PLX403 in V600E BRAF Melanoma$160,721
R41 · FY2014 · CA
A Small Molecule to Activate Cetuximab to Kill K-RAS Mutant Colorectal Tumors$147,010
R41 · FY2013 · CA